In this thought-provoking episode, Matt challenges the current narrative surrounding GLP-1 medications (like Ozempic and Wegovy) and obesity treatment.

He poses a crucial question: Are we focusing too much on survival instead of helping people truly thrive?

Key Points:

• The difference between surviving and thriving in healthcare

• Why treating obesity as purely a genetic disease might be misguided

• Three major concerns about GLP-1 medications:

• Downstream effects (vitamin absorption, gut health, muscle loss)
• Loss of essential healthy habits
• No clear exit strategy from the medication